A Phase 1 interventional study of M4112 in Metastatic or Locally Advanced Unresectable Solid Tumors, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-06.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Merck KGaA, Darmstadt, Germany.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 1, and was the 18th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 892 are open to participants now.
Browse Neoplasm Metastasis studies →None of the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Neoplasm Metastasis, anywhere →
Of the 691 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 5 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 141 across the 17 interventional studies, 438 across the 4 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Drug: M4112
Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Drug: M4112
Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Drug: M4112
Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Drug: M4112
Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Drug: M4112
All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
DLTs was assessed as per NCI CTCAE v 4.03. DLT defined as any Grade greater than or equal (\>=) 3 nonhematological AE or Immune-related adverse event (irAE) assessed by Investigator or Sponsor during first Cycle (first 28 days) of study treatment. Asymptomatic Grade \>= 3 lipase or amylase elevation not associated with clinical manifestations of pancreatitis. Any TEAE observed in subsequent cycle. Any Grade 4 neutropenia of \>= 5 days duration, Grade \>= 3 febrile neutropenia, Grade 3 hemoglobin decrease despite blood transfusion or erythroid growth factor. Grade 4 hemoglobin decrease assessed as related to study drug. Any Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding. Any Grade \>= 3 clinical signs and symptoms related to increased QTc.
Time frame: Cycle 1 (Each Cycle is of 28 days)
Part 1A Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Who Experienced a Treatment Related Adverse Events (TRAE) According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
An adverse event (AE) was defined as any untoward medical occurrence in participant which does not necessarily have casual relationship with treatment was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Treatment related AE was defined as having a "Possible" or "Related" relationship to study treatment, as assessed by the Investigator.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
The laboratory measurements included hematology, biochemistry and hormonal tests. Number of participants with any clinically significant abnormalities in laboratory measurements were reported. Clinical significance was determined by the investigator.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital signs assessment included blood pressure, pulse rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. Number of participants with on-treatment shift in ECOG PS Score from 0 to 1 were reported.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities
A complete physical examination (including, general appearance, skin, pulmonary, cardiovascular, gastrointestinal, external genitourinary only as medically relevant, lymphatic, neurologic and musculoskeletal systems, head/neck, extremities, eyes, ears, nose, throat, and cognitive status) was performed. Number of participants with clinical significant change from baseline in physical examination abnormalities were reported. Clinical significance was determined by the investigator.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post Dose AUC(0-8h) of M4112
Area under the drug concentration-time curve from 0 to 8 h post dosing for M4112. AUC0-8 was calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of M4112
Pharmacokinetic PK parameter Cmax was obtained directly from the plasma concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Time to Reach Maximum Plasma Concentration (Tmax) of M4112
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (AUC0-8/Dose) of M4112
Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 h postdose divided by dose.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4112
Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M4112
Accumulation ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours After Administration (Racc\[AUC0-8h\]) of M4112 was reported. Racc(AUC0-8h) calculated as AUC0-8h, on Cycle 1 Day 15 divided by AUC0-8h on Cycle 1 Day 1.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4112
Accumulation ratio for Cmax was calculated as Cmax, Cycle 1 Day 15 divided by Cmax, Cycle 1 Day 1.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Part 1A Dose Escalation: Pre-dose Observed Plasma Concentration (Cpre) of M4112
Maximum pre-dose observed plasma concentration was reported.
Time frame: Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)
Part 1A Dose Escalation: Dose Normalized Pre-dose Observed Plasma Concentration (Cpre/Dose) of M4112
Dose normalized pre-dose observed plasma concentration (Cpre/dose) of M4112 was reported.
Time frame: Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)
Part 1A Dose Escalation: Slope of Concentration-QTc (cQTc) Regression of M4112
Time-matched, replicate ECGs and PK samples collected in the dose-escalation phase and planned to analyze QTC response using slope analysis of exposure/response.
Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months
Part 1A Dose Escalation: Number of Participants With Best Overall Response (BOR)
BOR was determined according to Response Evaluation Criteria in Solid Tumors version1.1(RECIST 1.1).Best response obtained among all tumor assessment visits after the date of first study drug administration until documented disease progression. BOR rate is defined as the number of participants with BOR was either confirmed complete response (CR) partial response (PR), stable disease (SD) and progressive disease (PD) relative to the number of participants belonging to the study of interest. CR:Disappearance of all target lesions; PR:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; PD:At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months
Part 1A Dose Escalation: Duration of Response
Duration of response defined as time from first documentation of objective response complete response (CR) or partial response (PR) whichever is first recorded) to date of first documentation of objective progression of disease or death due to any cause whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of longest diameter (SLD) of all lesions.
Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months
Part 1A Dose Escalation: Disease Control Rate
Disease control was defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD. CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. Percentage of participants with disease control were reported.
Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months
Part 1A Dose Escalation: Time to Tumor Response
Tumor response was defined as the presence of at least 1 confirmed complete response (CR) or confirmed partial response (PR) as judged by RECIST version 1.1. CR was defined for target lesions (TLs) as the disappearance of all lesions, and for non-target lesions (NTLs) as the disappearance of all non-target non-measurable lesions and/or normalization of serum levels of tumor markers. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs.
Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months
Part 1A Dose Escalation: Progression Free Survival Time (PFS)
Progression free survival time defined as time from start date to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months
First Participant First Visit: 03-Oct-2017 Last Participant Last Visit: 14-Jan-2019.
| Milestone | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
DLTs was assessed as per NCI CTCAE v 4.03. DLT defined as any Grade greater than or equal (\>=) 3 nonhematological AE or Immune-related adverse event (irAE) assessed by Investigator or Sponsor during first Cycle (first 28 days) of study treatment. Asymptomatic Grade \>= 3 lipase or amylase elevation not associated with clinical manifestations of pancreatitis. Any TEAE observed in subsequent cycle. Any Grade 4 neutropenia of \>= 5 days duration, Grade \>= 3 febrile neutropenia, Grade 3 hemoglobin decrease despite blood transfusion or erythroid growth factor. Grade 4 hemoglobin decrease assessed as related to study drug. Any Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding. Any Grade \>= 3 clinical signs and symptoms related to increased QTc.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 | 0 | 0 | 0 | 0 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in participant which does not necessarily have casual relationship with treatment was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Treatment related AE was defined as having a "Possible" or "Related" relationship to study treatment, as assessed by the Investigator.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 3 | 3 | 3 |
| Any Related TEAE | 3 | 2 | 1 | 3 | 3 |
The laboratory measurements included hematology, biochemistry and hormonal tests. Number of participants with any clinically significant abnormalities in laboratory measurements were reported. Clinical significance was determined by the investigator.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | 1 | 0 | 0 | 0 | 1 |
Vital signs assessment included blood pressure, pulse rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs | 2 | 0 | 1 | 1 | 1 |
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. Number of participants with on-treatment shift in ECOG PS Score from 0 to 1 were reported.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1 | 1 | 0 | 1 | 0 | 1 |
A complete physical examination (including, general appearance, skin, pulmonary, cardiovascular, gastrointestinal, external genitourinary only as medically relevant, lymphatic, neurologic and musculoskeletal systems, head/neck, extremities, eyes, ears, nose, throat, and cognitive status) was performed. Number of participants with clinical significant change from baseline in physical examination abnormalities were reported. Clinical significance was determined by the investigator.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities | 0 | 0 | 0 | 0 | 0 |
Area under the drug concentration-time curve from 0 to 8 h post dosing for M4112. AUC0-8 was calculated according to the mixed log-linear trapezoidal rule.
| nanogram*hour per milliliter (ng*h/mL) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 3550 ± 14.4 | 8740 ± 13.6 | 27700 ± 21.4 | 50400 ± 7.7 | 14600 ± 85.1 |
| Cycle 1 Day 15 | 4790 ± 25.4 | 7580 ± 11.5 | 31500 ± 28.8 | 59500 ± 12.7 | NA ± NA |
Pharmacokinetic PK parameter Cmax was obtained directly from the plasma concentration versus time curve.
| nanogram per milliliter (ng/mL) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 806 ± 9.9 | 2110 ± 13.6 | 7670 ± 39.6 | 11700 ± 24.6 | 2770 ± 83.6 |
| Cycle 1 Day 15 | 975 ± 34.9 | 1720 ± 20.5 | 6560 ± 27.4 | 12100 ± 2.2 | NA ± NA |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1.08 (1.08 to 2.12) | 2.10 (2.07 to 3.08) | 1.08 (1.07 to 1.08) | 1.00 (0.97 to 1.07) | 2.08 (2.07 to 4.12) |
| Cycle 1 Day 15 | 3.08 (2.12 to 4.13) | 2.10 (1.00 to 6.08) | 1.08 (0.50 to 3.00) | 1.03 (0.93 to 2.17) | NA (2.00 to 2.00) |
Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 h postdose divided by dose.
| ng*h/mL/mg | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 35.5 ± 14.4 | 43.7 ± 13.6 | 69.1 ± 21.4 | 84.0 ± 7.7 | 18.2 ± 85.1 |
| Cycle 1 Day 15 | 47.9 ± 25.4 | 37.9 ± 11.5 | 78.8 ± 28.8 | 99.2 ± 12.7 | NA ± NA |
Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose.
| ng/mL/mg | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 8.06 ± 9.9 | 10.5 ± 13.6 | 19.2 ± 39.6 | 19.6 ± 24.6 | 3.47 ± 83.6 |
| Cycle 1 Day 15 | 9.75 ± 34.9 | 8.58 ± 20.5 | 16.4 ± 27.4 | 20.2 ± 2.2 | NA ± NA |
Accumulation ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours After Administration (Racc\[AUC0-8h\]) of M4112 was reported. Racc(AUC0-8h) calculated as AUC0-8h, on Cycle 1 Day 15 divided by AUC0-8h on Cycle 1 Day 1.
| Ratio | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M4112 | 1.35 ± 11.4 | 0.868 ± 15.3 | 1.14 ± 50.1 | 1.18 ± 9.4 | NA ± NA |
Accumulation ratio for Cmax was calculated as Cmax, Cycle 1 Day 15 divided by Cmax, Cycle 1 Day 1.
| Ratio | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4112 | 1.21 ± 24.8 | 0.815 ± 7.0 | 0.856 ± 66.8 | 1.03 ± 23.0 | NA ± NA |
Maximum pre-dose observed plasma concentration was reported.
| ng/mL | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 156 ± 58.2 | 96.5 ± 85.0 | 1240 ± 51.6 | 4410 ± 54.5 | 5200 ± 105.4 |
| Cycle 1 Day 15 | 221 ± 20.5 | 199 ± 53.9 | 1630 ± 45.7 | 3380 ± 42.4 | NA ± NA |
| Cycle 2 Day 1 | 128 ± 67.7 | NA ± NA | 957 ± 72.1 | NA ± NA | NA ± NA |
Dose normalized pre-dose observed plasma concentration (Cpre/dose) of M4112 was reported.
| ng/mL/mg | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 1.56 ± 58.2 | 0.482 ± 85.0 | 3.11 ± 51.6 | 7.35 ± 54.5 | 6.50 ± 105.4 |
| Cycle 1 Day 15 | 2.21 ± 20.5 | 0.997 ± 53.9 | 4.08 ± 45.7 | 5.63 ± 42.4 | NA ± NA |
| Cycle 2 Day 1 | 1.28 ± 67.7 | NA ± NA | 2.39 ± 72.1 | NA ± NA | NA ± NA |
Time-matched, replicate ECGs and PK samples collected in the dose-escalation phase and planned to analyze QTC response using slope analysis of exposure/response.
No measurements were reported for this outcome.
BOR was determined according to Response Evaluation Criteria in Solid Tumors version1.1(RECIST 1.1).Best response obtained among all tumor assessment visits after the date of first study drug administration until documented disease progression. BOR rate is defined as the number of participants with BOR was either confirmed complete response (CR) partial response (PR), stable disease (SD) and progressive disease (PD) relative to the number of participants belonging to the study of interest. CR:Disappearance of all target lesions; PR:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; PD:At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
| Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 | 0 |
| Stable Disease | 2 | 3 | 3 | 1 | 0 |
| Progressive Disease | 1 | 0 | 0 | 2 | 2 |
Duration of response defined as time from first documentation of objective response complete response (CR) or partial response (PR) whichever is first recorded) to date of first documentation of objective progression of disease or death due to any cause whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of longest diameter (SLD) of all lesions.
No measurements were reported for this outcome.
Disease control was defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD. CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. Percentage of participants with disease control were reported.
| Percentage of Participants | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Disease Control Rate | 66.7 (9.4 to 99.2) | 100 (29.2 to 100.0) | 100 (29.2 to 100.0) | 33.3 (0.8 to 90.6) | 0.0 (0.0 to 70.8) |
Tumor response was defined as the presence of at least 1 confirmed complete response (CR) or confirmed partial response (PR) as judged by RECIST version 1.1. CR was defined for target lesions (TLs) as the disappearance of all lesions, and for non-target lesions (NTLs) as the disappearance of all non-target non-measurable lesions and/or normalization of serum levels of tumor markers. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs.
No measurements were reported for this outcome.
Progression free survival time defined as time from start date to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
| Months | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| Part 1A Dose Escalation: Progression Free Survival Time (PFS) | 3.7 (1.9 to 8.1) | 5.5 (3.9 to 5.5) | NA (2.1 to 10.2) | 1.8 (1.1 to 3.7) | 1.2 (0.0 to 1.2) |
Collected over Baseline up to safety follow-up visit, assessed up to 15.4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A Dose Escalation: M4112 100 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1A Dose Escalation: M4112 200 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1A Dose Escalation: M4112 400 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1A Dose Escalation: M4112 600 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1A Dose Escalation: M4112 800 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| AscitesGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 |
| Disease progressionGeneral disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Dermatitis allergicSkin and subcutaneous tissue disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 |
| Event | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 2/3 | 0/3 |
| DyspepsiaGastrointestinal disorders | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| VomitingGastrointestinal disorders | 2/3 | 1/3 | 0/3 | 1/3 | 0/3 |
| FatigueGeneral disorders | 2/3 | 0/3 | 1/3 | 1/3 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 0/3 | 0/3 | 0/3 | 2/3 |
| Lipase increasedInvestigations | 0/3 | 1/3 | 0/3 | 2/3 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Anaemia of malignant diseaseBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 1/3 | 0/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 |
| PalpitationsCardiac disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Age, Continuous(Years) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 60.7 ± 14.84 | 54.7 ± 8.33 | 43.0 ± 9.54 | 67.7 ± 7.51 | 62.3 ± 14.84 | 57.7 ± 13.04 |
| Sex: Female, Male(Participants) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 3 | 3 | 13 |
| Male | 1 | 0 | 1 | 0 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 1 | 0 | 3 |
| Not Hispanic or Latino | 2 | 3 | 2 | 2 | 3 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1A Dose Escalation: M4112 100 mg | Part 1A Dose Escalation: M4112 200 mg | Part 1A Dose Escalation: M4112 400 mg | Part 1A Dose Escalation: M4112 600 mg | Part 1A Dose Escalation: M4112 800 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 0 | 1 | 3 |
| White | 2 | 3 | 2 | 3 | 2 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Jan 2019, 15 months.
Results were first posted in Feb 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EMD Serono Research & Development Institute, Inc. →